{"disease":{"id":"horizontal-forehead-lines","name":"Horizontal forehead lines","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"incobotulinumtoxina","indication_name":"Moderate to severe horizontal forehead lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Horizontal forehead lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04622254","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Merz North America, Inc.","has_results":true},{"nct_id":"NCT04594213","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":362,"lead_sponsor_name":"Merz North America, Inc.","has_results":true},{"nct_id":"NCT05222607","title":"Longitudinal Evaluation and Real-world Evidence of NT201","phase":"","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Merz North America, Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}